| Budget Amount *help |
¥18,980,000 (Direct Cost: ¥14,600,000、Indirect Cost: ¥4,380,000)
Fiscal Year 2012: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2011: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2010: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
|
|---|
| Research Abstract |
Serine threonine Akt is a core intra-cellular survival regulator. In this study, we demonstrated that the functional interaction of NS1 with Akt and clarified that the functional importance of influenza virus NS1 with Akt in biocmical analysis. The results together supported the functional importance of influenza virus NS1 with Akt.We clarified that TCL1b functions as an Akt kinase co-activator and exhibitsoncogenicity both in vitro and in vivo using biochemical analysis, bioinformatics, and generation of TCL1b transgenic mice which resulted in angiosarcoma. By immunohistochemistry, most of human angiosarcoma samples and various cancer tissues were positively stained by both anti-TCL1b and anti-phospho-Akt antibodies. Moreover,TCL1b structure-based inhibitor “TCL1b-Akt-in” inhibited Akt kinase activity, hence, suppressed cellular proliferation of sarcoma. The current study disclosed TCL1b bears oncogenicity, and hence serves as a novel therapeutic target for human neoplasticdiseases.
|
